ST Jinhua released its 2026 interim report. First-half net profit attributable to the parent company was 790,000 yuan, down 87.25% year on year. Operating revenue was 246 million yuan, up 1.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 9.19 million yuan, up 35.3% year on year. Net operating cash flow was negative 64.38 million yuan. Second-quarter operating revenue was 119 million yuan, down 11.4% year on year, with a net loss attributable to the parent of 3.12 million yuan. The company's main business remains research, development, production and sales of pharmaceuticals, with a product line covering chemical drugs, proprietary Chinese medicines, active pharmaceutical ingredients and health products.
Ginwa Enterprise Group IncFirst-half net profit attributable to parent down 87.25% year on year.
